Initiation of complement activation following oxidative stress. In vitro and in vivo observations

Molecular Immunology

Volumn 41, Issue 2-3, 2004, Pages 165-171

  Hart, Melanie L ^a   Walsh, Mary C ^a   Stahl, Gregory L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gastrointestinal; Ischemia; Lectin; MBL; Myocardium; Reperfusion

Indexed keywords

COBROTOXIN; COMPLEMENT; COMPLEMENT INHIBITOR; ESTERASE INHIBITOR; MONOCLONAL ANTIBODY; PEXELIZUMAB; PROTEIN C1 ESTERASE INHIBITOR; TP 10; UNCLASSIFIED DRUG;

CAPILLARY LEAK SYNDROME; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE MODEL; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; ISCHEMIA; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; POSTOPERATIVE CARE; PRIORITY JOURNAL; REPERFUSION INJURY; SIDE EFFECT; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; INFLAMMATION; OXIDATIVE STRESS; REPERFUSION INJURY;

EID: 2442700517     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2004.03.013     Document Type: Conference Paper

References (57)

1. Amsterdam E.A., Stahl G.L., Pan H.-L., Rendig S.V., Fletcher M.P., Longhurst J.C. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am. J. Physiol. Heart Circ. Physiol. 268:1995;H448-H457
2. Brock R.W., Nie R.G., Harris K.A., Potter R.F. Kupffer cell-initiated remote hepatic injury following bilateral hindlimb ischemia is complement dependent. Am. J. Physiol. Gastrointest. Liver Physiol. 280:2001;G279-G284
3. Buerke M., Murohara T., Lefer A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 91:1995;393-402
4. Buerke M., Prüfer D., Dahm M., Oelert H., Meyer J., Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J. Pharmacol. Exp. Ther. 286:1998;429-438
5. Collard C.D., Agah A., Reenstra W., Buras J., Stahl G.L. Endothelial nuclear factor-kappaB translocation and vascular cell adhesion molecule-1 induction by complement: inhibition with anti-human C5 therapy or cGMP analogues. Arterioscler. Thromb. Vasc. Biol. 19:1999;2623-2629
6. Collard C.D., Agah A., Stahl G.L. Complement activation following reoxygenation of hypoxic human endothelial cells: role of intracellular reactive oxygen species, NF-kappaB and new protein synthesis. Immunopharmacology. 39:1998;39-50
7. Collard C.D., Montalto M.C., Reenstra W.R., Buras J.A., Stahl G.L. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am. J. Pathol. 159:2001;1045-1054
8. Collard C.D., Vakeva A., Bukusoglu C., Zund G., Sperati C.J., Colgan S.P., Stahl G.L. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation. 96:1997;326-333
9. Collard C.D., Vakeva A., Morrissey M.A., Agah A., Rollins S.A., Reenstra W.R., Buras J.A., Meri S., Stahl G.L. Complement activation after oxidative stress: role of the lectin complement pathway. Am. J. Pathol. 156:2000;1549-1556
10. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., Schmal H., Friedl H.P., Ward P.A. Protective effects of C5a blockade in sepsis. Nat. Med. 5:1999;788-792
11. de Zwaan C., Kleine A.H., Diris J.H., Glatz J.F., Wellens H.J., Strengers P.F., Tissing M., Hack C.E., Dieijen-Visser M.P., Hermens W.T. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur. Heart J. 23:2002;1670-1677
12. Fiane A.E., Videm V., Lingaas P.S., Heggelund L., Nielsen E.W., Geiran O.R., Fung M., Mollnes T.E. Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation. 108:2003;849-856
13. Fitch J.C.K., Rollins S.A., Matis L.A., Alford B.L., Aranki S., Collard C.D., Dewar M., Elefteriades J., Hines R., Kopf G., Kraker P., Li L., O'Hara R., Rinder C.S., Rinder H.M., Shaw R., Smith B., Stahl G.L., Shernan S.K. Pharmacology and biological efficacy of a recombinant, humanized, single chain antibody, C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery utilizing cardiopulmonary bypass. Circulation. 100:1999;2499-2509
14. Foxall C., Watson S.R., Dowbenko D., Fennie C., Lasky L.A., Kiso M., Hasegawa A., Asa D., Brandley B.K. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J. Cell Biol. 117:1992;895-902
15. Fruchterman T.M., Spain D.A., Wilson M.A., Harris P.D., Garrison R.N. Complement inhibition prevents gut ischemia and endothelial cell dysfunction after hemorrhage/resuscitation. Surgery. 124:1998;782-791
16. Granger C.B., Mahaffey K.W., Weaver W.D., Theroux P., Hochman J.S., Filloon T.G., Rollins S., Todaro T.G., Nicolau J.C., Ruzyllo W., Armstrong P.W. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 108:2003;1184-1190
17. Harlan J.M., Winn R.K. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit. Care Med. 30:2002;S214-S219
18. Hart M.L., Ceonzo K.A., Buras J.A., Stahl G.L. Gastrointestinal ischemia-reperfusion injury is complement-dependent but not dependent on C1q. Mol. Immunol. 40(2-4):2003;187
19. Hill J.H., Ward P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts in rats. J. Exp. Med. 133:1971;885-900
20. Horstick G. C1-esterase inhibitor in ischemia and reperfusion. Immunobiology. 205:2002;552-562
21. Horstick G., Berg O., Heimann A., Gotze O., Loos M., Hafner G., Bierbach B., Petersen S., Bhakdi S., Darius H., Horstick M., Meyer J., Kempski O. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation. 104:2001;3125-3131
22. Horstick G., Heimann A., Gotze O., Hafner G., Berg O., Boehmer P., Becker P., Darius H., Rupprecht H.-J., Loos M., Bhakdi S., Meyer J., Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 95:1997;701-708
23. Ito W., Schäfer H.J., Bhakdi S., Klask R., Hansen S., Schaarschmidt S., Schofer J., Hugo F., Hamdoch T., Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc. Res. 32:1996;294-305
24. Iwata A., Harlan J.M., Vedder N.B., Winn R.K. The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials. Blood. 100:2002;2077-2080
25. Jiang H.X., Wagner E., Zhang H.M., Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. 194:2001;1609-1616
26. Jordan J.E., Montalto M.C., Stahl G.L. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation. 104:2001;1413-1418
27. Karpel-Massler G., Fleming S.D., Kirschfink M., Tsokos G.C. Human c1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury(1). J. Surg. Res. 115:2003;247-256
28. Kilgore K.S., Flory C.M., Miller B.F., Evans V.M., Warren J.S. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am. J. Pathol. 149:1996;953-961
29. Kyriakides C., Austen W. Jr., Wang Y., Favuzza J., Kobzik L., Moore F.D. Jr., Hechtman H.B. Skeletal muscle reperfusion injury is mediated by neutrophils and the complement membrane attack complex. Am. J. Physiol. 277:1999;C1263-C1268
30. Lekowski R., Collard C.D., Reenstra W.R., Stahl G.L. Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation. Protein Sci. 10:2001;277-284
31. Lennon P.F., Collard C.D., Morrissey M.A., Stahl G.L. Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences. Am. J. Physiol. Heart Circ. Physiol. 270:1996;H1924-H1932
32. MacLean D., Fishbein M.C., Braunwald E., Maroko P.R. Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J. Clin. Invest. 61:1978;541-551
33. Mahaffey K.W., Granger C.B., Nicolau J.C., Ruzyllo W., Weaver W.D., Theroux P., Hochman J.S., Filloon T.G., Mojcik C.F., Todaro T.G., Armstrong P.W. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 108:2003;1176-1183
34. Maroko P.R., Carpenter C.B., Chariello M. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J. Clin. Invest. 61:1978;661-670
35. Matsushita M., Thiel S., Jensenius J.C., Terai I., Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J. Immunol. 165:2000;2637-2642
36. Montalto M.C., Collard C.D., Buras J.A., Reenstra W.R., McClaine R., Gies D.R., Rother R.P., Stahl G.L. A keratin peptide inhibits mannose-binding lectin. J. Immunol. 166:2001;4148-4153
37. Mulligan M.S., Schmid E., Beck-Schimmer B., Till G.O., Friedl H.P., Brauer R.B., Hugli T.E., Miyasaka M., Warner R.L., Johnson K.J., Ward P.A. Requirement and role of C5a in acute lung inflammatory injury in rats. J. Clin. Invest. 98:1996;503-512
38. Pinckard R.N., O'Roarke R.A., Crawford M.H. Complement localization and mediation of ischemic injury in baboon myocardium. J. Clin. Invest. 66:1980;1050-1056
39. Sahul A., Lambris J.D. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology. 49:2000;133-148
40. Shernan S.K., Collard C.D. Role of the complement system in ischaemic heart disease: potential for pharmacological intervention. Biodrugs. 15:2001;595-607
41. Smith E.F. III, Griswold D.E., Egan J.W., Hillegass L.M., Smith R.A.G., Hibbs M.J., Gagnon R.C. Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). Eur. J. Pharmacol. 236:1993;477-481
42. Spain D.A., Fruchterman T.M., Matheson P.J., Wilson M.A., Martin A.W., Garrison R.N. Complement activation mediates intestinal injury after resuscitation from hemorrhagic shock. J. Trauma Injury Infect. Crit. Care. 46:1999;224-232
43. Stahl G.L., Reenstra W.R., Frendl G. Complement mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex. Circ. Res. 76:1995;575-583
44. Stahl G.L., Xu Y., Hao L., Miller M., Buras J.A., Fung M., Zhao H. Role for the alternative complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 162:2003;449-455
45. Thurman J.M., Ljubanovic D., Edelstein C.L., Gilkeson G.S., Holers V.M. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J. Immunol. 170:2003;1517-1523
46. Toomayan G.A., Chen L.E., Jiang H.X., Qi W.N., Seaber A.V., Frank M.M., Urbaniak J.R. C1-esterase inhibitor and a novel peptide inhibitor improve contractile function in reperfused skeletal muscle. Microsurgery. 23:2003;561-567
47. Vakeva A., Agah A., Rollins S.A., Matis L.A., Li L., Stahl G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 97:1998;2259-2267
48. Vakeva A., Meri S. Complement activation and regulator expression after anoxic injury of human endothelial cells. APMIS. 106:1998;1149-1156
49. Wada K., Montalto M.C., Stahl G.L. Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology. 120:2001;126-133
50. Walsh M.C., Bourcier T., Takahashi M., Stahl G.L. Complement activation and tissue injury following myocardial ischemia and reperfusion is C1q independent. Mol. Immunol. 40(2-4):2003;215
51. Weiser M.R., Williams J.P., Moore F.D. Jr., Kobzik L., Ma M., Hechtman H.B., Carroll M.C. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183:1996;2343-2348
52. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C.J., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 249:1990;146-151
53. Williams J.P., Pechet T.T., Weiser M.R., Reid R., Kobzik L., Moore F.D. Jr., Carroll M.C., Hechtman H.B. Intestinal reperfusion injury is mediated by IgM and complement. J. Appl. Physiol. 86:1999;938-942
54. Wong M.S., Lara T.M., Kobzik L., Rounds J.D., Robinson M.K., Jacobs D.O. Hindlimb ischemia-reperfusion increases complement deposition and glycolysis. J. Surg. Res. 85:1999;130-135
55. Zacharowski K., Otto M., Hafner G., Marsh H.C. Jr., Thiemermann C. Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Br. J. Pharmacol. 128:1999;945-952
56. Zhao H., Montalto M.C., Pfeiffer K.J., Hao L., Stahl G.L. Murine model of gastrointestinal ischemia associated with complement dependent injury. J. Appl. Physiol. 93:2002;338-345
57. Zhou W., Farrar C.A., Abe K., Pratt J.R., Marsh J.E., Wang Y., Stahl G.L., Sacks S.H. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 105:2000;1363-1371